liabilities under financial lease agreements 33 33 -2% Other non-current liabilities 340 349 -3% Total Current Liabilities 2,408 2,517 -4% Long-term loans, net of current portion from financial institutions 655

purchase agreement and/or relevant agreements and complete the transfer of BS Myco Biotech shares on June 12, 2019. This Acquisition is considered as the assets acquisition transaction of listed company and

with those disclosed by Huntsman, on signing of the definitive agreements. The Transaction will broaden IVL’s expertise of operating US Gulf Coast (USGC) Integrated Oxides facility through operational

from banks 38.64 38.64 - - Current portion of liabilities under finance lease agreements 8.34 1.45 6.90 476.79 Short-term borrowing from third party 2.50 - 2.50 n/a Other current liabilities 21.38 22.16

payables and other payables of Baht 34 million, current portion of liabilities under lease agreements of Baht 11 million due to effects of TFRS16 adoption in 1 January 2020 as described in prior paragraph

Agreements On February 20, 2020, the Company/the subsidiary and EXAT signed the Second Stage Expressway Agreement (Amendment) and the Bang Pa-in - Pak Kret Expressway Agreement (Amendment) which extend the

3.2 (16.7) (35.2) Total Revenue 423.6 100.0 1,462.6 100.0 (1,039.0) (71.0) 1 Backlog include only sale with sales and purchase agreements 2 Calculated from interest bearing debt to equity Management

was mainly due to (1) an increase in cash and cash equivalents and (2) a decrease in liabilities under lease agreements. The debt-to-equity ratio decreased to 1.11 as of 31 March 2021 compared to 1.22

lease agreements 16.2 - 16.2 100.0% Provision for long-term employee benefits 130.5 97.8 32.7 33.4% Total liabilities 3,767.0 2,842.7 924.3 32.5% Liabilities As of March 31, 2020, the Company’s total

leasing agreements on Financial Statement followed to TFRS 16 Leases. 4.2 Liabilities The total liability as at 31 March 2020 was increased from the year 2019 by Baht 73.80 million or 20.39 percent